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Background: Wiskott-Aldrich syndrome (WAS) is a rare X-
linked disorder characterized by a triad of immunodeﬁ-
ciency, eczema and thrombocytopenia. This is as a result of
mutation in the WASP gene that regulates actin polymeri-
zation in hematopoietic cells. Currently, stem cell transplant
(SCT) is the most reliable curative treatment with excellent
results for patients with HLA-matched family or unrelated
donors. However, mixed donor chimerism even in the
setting of full myeloablative regimens is still a signiﬁcant
problem since mixed chimerism affecting the myeloid
compartment may result in persistent thrombocytopenia.
Thus, identifying factors associated with mixed donor
chimerism after SCT in WAS patients is extremely
important.
Methods: We performed a retrospective chart review of
eleven children who underwent allogeneic transplant for
WAS to identify any factors (i.e. pretransplant health of the
patients, degree of thrombocytopenia, conditioning regimen,
infection, peri-transplant factors, TH2 ﬂare) that may be
associated with mixed donor chimerism.
Results: The median age at transplant was 16 months
(range 3-39) and the donor was MRD in 4, MUD in 5 and
MMUD in 2. All patients received bone marrow apart from
one who received cord. The mean WAS score was 2.7 (range
1-5) and diagnosis was conﬁrmed by genetic testing in all
patients. All were conditioned with myeloablative regimens.
Nine received busulfan, cyclophosphamide, Ara-C or ﬂu-
darabine and campath while 2 patients got busulfan,
cyclophosphamide and ATG. The median nucleated cell dose
from the marrow was 5.3 x 109/kg (range 3 to 7.9). The
median times to neutrophil and platelet engraftment were
22.5 (range 13-27) and 19 (range 17-31) days respectively.
The overall survival by Kaplan Meier analysis is 91%, 95%CI:
51%-99% at 2 year post transplant. Only one patient devel-
oped grade IV aGvHD and died on Day +99. Five of eleven
(45%) had mixed donor chimerism, (range: 7-50%). Of these
5 patients, 2 had normalization of the platelet count despite
the mixed chimerism, 2 had full donor chimerism after
receiving a second transplant with the same donor, and 1
remains transfusion dependent awaiting a 2nd transplant.
No statistically signiﬁcant difference was found between
WAS scores, donor type, conditioning, stem cell source, age
at transplant and mixed chimerism amongst the eleven
patients.
Conclusions: Although the overall survival of our patient
populationwasexcellent, it doesnot reﬂect auniformresult intermsof engraftment.Noneof ourperi-transplant parameters
are predictive of mixed chimerism or engraftment outcome.
More correlative work is needed to assess genotype-pheno-
type risk factors for engraftment as well as pre transplant
immunologic and disease states to better assess the risk of
mixed chimerism and guide interventions to promote en-
graftment.320
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Currently, in our environment, 50% of patients requiring
transplantation cannot undergo this procedure due to lack of
a donor.
Twenty patients with different pathologies Eleven patients
had graft acceptance (55%) with complete chimerism. Nine
(45%) patients had primary graft failure. Of the patients
subjected to HT as rescue in case of cord graft failure, it was
noted that 100% of the patients are alive after 40 months of
follow-up with a statistically signiﬁcant difference (p ¼ 0.02)
compared with those subjected to HT as the primary choice.
This case review describes HT as a therapeutic tool in chil-
dren without an available donor. Our objective was to
describe the clinical features, complications and deaths in a
series of children undergoing HT in the Instituto Nacional de
Pediatria (INP) since 2009.
We included all patients undergoing HT between July 2009
and November 2012 .
Conditioning was done with ﬂudarabine (30 mg/m2) for 2
days, anti-thymocyte globulin (1.5 mg/kg/day) for 3 days,
nodal radiotherapy (7 Gy) andmelphalan (70mg/m2/day) for
2 days. For graft vs. host disease (GVHD) prophylaxis, cyclo-
sporine (6 mg/kg/day) was used from day -1.
The method of CD34+ selection was contemplated for pa-
tients with immunodeﬁciency and CD3+ depletion for pa-
tients with oncology/hematology diseases.
For bivariate analysis of qualitative variables, c2and Student t
test were performed. OS and DFS curves were performed
with the Kaplan-Meier method using SPSS v.20.0. Differences
between the rates of OS or DFS based on cell dose, age,
gender, and paternal or maternal donor were made using the
log-rank test; p<0.05 was considered signiﬁcant.
Themedian of cells infused was as follows: CD34+ 10.9 x 106/
kg (range: 2 to 32 x 106/kg), CD3+ 14.2 x 105/kg and CD19+
3.4 x 105/kg.
11 patients achieved graft (55%) with complete chimerism.
Nine patients (45%) had primary graft failure. Of the 11 pa-
tients with complete chimerism, two patients had graft loss
due to relapse of ALL (at 4 and 12 months post-HT). In a third
case therewas loss of the graft due to cytomegalovirus (CMV)
at 21 months post-HT. Of the patients subjected to HT as
rescue in case of cord graft failure, it was noted that 100% of
the patients were alive at 40 months of follow-up with a
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those subjected to HT as a ﬁrst choice.
OS of 70% was reported at 40 months. OS and DFS for chil-
dren with leukemia was 75% and 40%, respectively. For
children with immunodeﬁciencies it was 65% and 15%,
respectively, with a 40-month follow-up321
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Purpose: Cytomegalovirus (CMV) infection remains a sig-
niﬁcant source of morbidity in pediatric hematopoietic stem
cell transplantation (HSCT). Current strategies for mitigating
the effect of CMV on outcome include weekly measurement
of CMV viral load in the blood through post-transplant day
100 and use of acyclovir prophylaxis in the peritransplant
period in patients at risk for CMV infection (patients inwhich
the HSCT donor or recipient had CMV IgG seropositivity
indicative of latent infection). Risk factors predicting CMV
infection in pediatric HSCT are not well understood, and
factors affecting recurrence of CMV viremia following an
initial episode have not been reported.
Methods: We performed a retrospective review of consec-
utive cases at our institution between 2011 and 2014 where
the recipient was at risk for CMV infection. We calculated
odds ratios (OR) and 95% conﬁdence intervals (CI) of CMV
reactivation as a function of HSCT characteristics. This study
was approved by the Institutional Review Board of the Dana-
Farber Cancer Institute.
Results: Out of a total of 91 at risk patients, 26 (29%) pa-
tients had CMV infection (deﬁned as CMV viremia without
target organ involvement) occurring at a median of 46 days
following HSCT (range: 9-127). One patient died from bi-
opsy-proven CMV pneumonitis. There was a trend towards
recipients with underlying malignant conditions having
increased risk of CMV infection compared to others
(OR¼2.3; 95% CI¼0.9-6.0; p¼0.08). There was a signiﬁ-
cantly increased risk of CMV infection in recipients of an
umbilical cord blood compared to other sources (OR¼9.45;
95% CI¼1.8-50.6; p¼0.009). Patients with acute graft-
versus-host disease (aGVHD) had a signiﬁcantly increased
risk of CMV infection (OR¼3.6; 95% CI¼1.1-12.1; p¼0.04).
All patients with viremia received a 14-day course of
antiviral and immunoglobulin therapy. Patients who failed
to clear the virus completely from the blood at the end of
14 days of therapy had no increased risk of CMV recurrence
(p¼0.2). A total of 6/26 (23%) HSCT recipients experienced
CMV recurrence, at a median of 33 days (range 9-74)
following initial CMV clearance. In the subset of recipients
who experienced a recurrence of CMV infection, there was
a trend toward increased treatment-related mortality
(TRM; OR¼9.5; 95% CI ¼ 0.7-132; p¼0.09). However,
among all recipients at risk, CMV viremia was not associ-
ated with increased TRM (p¼0.7).
Conclusions: Pediatric patients seropositive for CMV who
receive umbilical cord HSCTs have increased risk for CMV
viremia in the post-HSCT period. CMV infection is associ-
ated with aGVHD. If treated with antivirals, recurrence of
CMV can be prevented. Multiple episodes of CMV viremiamay be associated with increased TRM. This study
broadens understanding of CMV disease in pediatric HSCT,
and is the ﬁrst to analyze factors inﬂuencing recurrence of
CMV infection.322
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Familial hemophagocytic lymphohistiocytosis (FHLH) has
often been associated with high transplant-relatedmortality,
typically from a variety of causes in the ﬁrst 100 days post-
HSCT. We report a case of occult pulmonary hypertension
that developed 3 years after HSCT for FHLH. The patient was
born at 28 weeks with a NICU course consisting of mild
respiratory distress syndrome and unilateral grade II intra-
ventricular hemorrhage. At 2.5 months of age, he developed
fevers, splenomegaly, progressive pancytopenia, hypoﬁ-
brinogenemia, hyperferritinemia, and bone marrow hemo-
phagocytosis. He underwent initial treatment per HLH-2004
with good response. Genetic analysis revealed homozygous
perforin 1 mutations. He proceeded with a 5/6 cord blood
transplant with Bu/Cy/VP-16/ATG conditioning and GVHD
prophylaxis with cyclosporine and steroids. He achieved
successful engraftment with stable 100% donor chimerism.
Post-HSCT course was complicated by engraftment syn-
drome, steroid-responsive grade II skin and gut aGVHD, se-
vere VOD treatedwith deﬁbrotide, and prolonged intubation.
He developed persistent renal failure, presumably due to
chronic calcineurin toxicity. He underwent cadaveric renal
transplant 10 months after HSCT. Clinical care over the next
two years was all outpatient, but complicated by BK
nephropathy.
Two months prior to his death, he presented with
tachypnea and oxygen desaturation. CXR showed mild
peribronchial opacities. Respiratory viral panel and echo-
cardiogram were normal. His symptoms resolved quickly
with albuterol. He was re-admitted a week later with
similar symptoms. Repeat CXR and echocardiogram were
unchanged. Due to persistent symptoms, he underwent
bronchoscopy that was positive for P. jirovecii and was
treated with high-dose Bactrim. One month after
completing treatment, he presented to an outside ER with
acute onset of dyspnea. He rapidly decompensated into
PEA and was unable to be resuscitated. Autopsy showed
intimal and medial thickening of his pulmonary arteries
with marked luminal narrowing, consistent with pulmo-
nary arterial hypertension (PAH).
There is one prior case report of two pediatric FHLH patients
who died in the ﬁrst year post-HSCT with PAH discovered on
autopsy. Despite successful HSCT, there appears to be a
pathologic link between FHLH and PAH, both early and late
post-HSCT. PAH should be considered in any FHLH patient
with respiratory symptoms and improved screening tech-
niques are critically needed.
